Moderna (MRNA) Receives a Buy from Oppenheimer

By Ryan Adsit

Oppenheimer analyst Hartaj Singh assigned a Buy rating to Moderna (MRNAResearch Report) today and set a price target of $108.00. The company’s shares closed last Monday at $83.25.

According to, Singh is a 5-star analyst with an average return of 12.1% and a 48.1% success rate. Singh covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Alexion Pharmaceuticals, and Vertex Pharmaceuticals.

Moderna has an analyst consensus of Strong Buy, with a price target consensus of $66.56, which is a -22.7% downside from current levels. In a report issued on May 7, Needham also assigned a Buy rating to the stock with a $58.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $68.49 and a one-year low of $11.54. Currently, Moderna has an average volume of 18.8M.

Based on the recent corporate insider activity of 80 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MRNA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.